AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 221 min read$RVTY

Gonzales Anita sold $9K of RVTY

Gonzales Anita (Vice President and CAO) sold 85 shares of REVVITY, INC. (RVTY) at $109.48 on 2026-07-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gonzales Anita
Published Jul 22, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 22, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RVTY
Neutral
high confidence
Mentioned
$RVTY
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVTYNeutralLow
01

Why it matters

The disclosure provides transparency on an officer’s planned selling activity but does not introduce new company fundamentals or catalysts.

02

Market read

Primarily informational for insider-trading trackers; limited expected impact on trading decisions.

03

What to watch

The sale size is small ($9.3K) and does not include any buy/sell pattern context beyond this single transaction.

Relevance 2/10Novelty 2/10Timing: Filed on 2026-07-22 after-hours, reflecting a 2026-07-20 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Revvity, Inc.

Company-level read

Ticker impact

$RVTYNeutralHigh confidence
Context

Revvity CAO Anita Gonzales sold 85 shares on 2026-07-20 at $109.48/share under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a small, pre-planned open-market sale by an officer, with no accompanying guidance, operational change, or enforcement action disclosed.

Market effects

Sector

No sector read-across; this is company-specific insider transaction data only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with private concerns; traders may still monitor for follow-on sales.

Key entities

  • Equity issuer
    RVTY

    Revvity, Inc., the issuer of the Form 4 insider transaction.

  • Insider
    Anita Gonzales

    Vice President and CAO who sold 85 shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Related articles

AUG 9
$RVTYMedAI 8/10

Revvity Q2 Earnings Call Highlights

Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.

finance.yahoo.com6 min
AUG 6
$RVTYMed

Revvity, Inc. Q2 2026 Earnings Call Summary

Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.

yahoo.com6 min
AUG 5
$RVTYMedAI 8/10

Why Revvity (RVTY) Stock Is Up Today

Revvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.

financialcontent.com4 min
AUG 4
$RVTYMedAI 9/10

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.

tradingview.com6 min
AUG 4
$RVTYMedAI 8/10

Revvity (NYSE:RVTY) Reports Upbeat Q2 CY2026

Revvity (NYSE: RVTY) reported Q2 CY2026 results. Revenue rose 7.2% year on year to $729.7 million, exceeding analysts’ estimates by 3.2%. Full-year revenue guidance is $2.85 billion at the midpoint, 0.5% above estimates. Non-GAAP EPS was $1.41, 15.9% above consensus.

financialcontent.com4 min